GH Research (GHRS) Other Accumulated Expenses (2021 - 2026)
GH Research (GHRS) posted quarterly Other Accumulated Expenses of $4.2 million for Q4 2025, down 14.42% year-over-year from $5.0 million in Q4 2024, and down 31.65% quarter-over-quarter from $6.2 million in Q3 2025.
Analysis
GH Research (GHRS) Other Accumulated Expenses (2021 - 2026) Analysis & Trends
GH Research's Other Accumulated Expenses history runs 5 years deep, the most recent figure standing at $4.2 million for Q4 2025.
- In Q4 2025, Other Accumulated Expenses fell 14.42% year-over-year to $4.2 million; the TTM figure through Dec 2025 stood at $4.2 million (down 14.42% YoY), while the FY2025 annual figure was $4.2 million, down 14.42% from the prior year.
- Other Accumulated Expenses for Q4 2025 stood at $4.2 million, down from $6.2 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $6.6 million in Q3 2024, with the low at $819000.0 in Q3 2021.
- The 5-year median for Other Accumulated Expenses is $3.4 million (2023), against an average of $3.7 million.
- The sharpest annual moves came in 2023 and 2025: Other Accumulated Expenses surged 143.37% in 2023, then retreated 14.42% in 2025.
- GH Research's Other Accumulated Expenses stood at $3.0 million in 2021, then declined by 10.22% to $2.7 million in 2022, then gained by 7.09% to $2.9 million in 2023, then soared by 72.84% to $5.0 million in 2024, then dropped by 14.42% to $4.2 million in 2025.
- Business Quant data shows GHRS's Other Accumulated Expenses at $4.2 million in Q4 2025, $6.2 million in Q3 2025, and $6.2 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | GH Research | 1.72 Bn | 1.36 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.57 Mn |
| Mar 31, 2026 | 6.25 Mn |
| Dec 31, 2025 | 4.24 Mn |
| Sep 30, 2025 | 6.21 Mn |
| Jun 30, 2025 | 6.16 Mn |
| Mar 31, 2025 | 4.81 Mn |
| Dec 31, 2024 | 4.96 Mn |
| Sep 30, 2024 | 6.57 Mn |
| Jun 30, 2024 | 4.97 Mn |
| Mar 31, 2024 | 3.39 Mn |
| Dec 31, 2023 | 2.87 Mn |
| Sep 30, 2023 | 3.17 Mn |
| Jun 30, 2023 | 3.38 Mn |
| Mar 31, 2023 | 3.38 Mn |
| Dec 31, 2022 | 2.68 Mn |
| Sep 30, 2022 | 1.64 Mn |
| Jun 30, 2022 | 1.39 Mn |
| Mar 31, 2022 | 2.52 Mn |
| Dec 31, 2021 | 2.98 Mn |
| Sep 30, 2021 | 819,000.00 |